Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference
Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) announced its participation in SVB Leerink’s Virtual Global Healthcare Conference from February 14-18, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) announced its participation in SVB Leerink’s Virtual Global Healthcare Conference from February 14-18, 2022. A fireside chat is scheduled for February 18, 2022, at 1:00 PM ET. The company focuses on developing therapies for rare genetic mitochondrial diseases, with its lead product, REN001, aimed at enhancing mitochondrial function and ATP production. Reneo's innovations could significantly impact the treatment landscape for patients suffering from these conditions.
Details
News Market Reaction – RPHM
The recorded move for RPHM in the trading session of this news was -8.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be hosting a fireside chat and participating in one-on-one investor meetings at SVB Leerink’s Virtual Global Healthcare Conference taking place February 14-18, 2022.
Presentation details are as follows:
Date: Friday, February 18, 2022
Time: 1:00 PM ET
Format: Fireside chat
About Reneo Pharmaceuticals
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.